Aripiprazole for the treatment of pediatric bipolar I disorder: A 30-week, randomized, placebo-controlled study

Bipolar Disorders

Volumn 15, Issue 2, 2013, Pages 138-149

  Findling, Robert L ^a   Correll, Christoph U ^b   Nyilas, Margaretta ^c   Forbes, Robert A ^c   Mcquade, Robert D ^c   Jin, Na ^c   Ivanova, Svetlana ^c   Mankoski, Raymond ^d   Carson, William H ^c   Carlson, Gabrielle A ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e STONY BROOK UNIVERSITY   (United States)

Author keywords

Aripiprazole; Bipolar disorder; Pediatric; Treatment

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; AKATHISIA; ARTHRALGIA; ARTICLE; BACKACHE; BIPOLAR DISORDER; BLURRED VISION; CHILD; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; DYSTONIA; EPISTAXIS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERSALIVATION; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE STRAIN; MUSCULOSKELETAL PAIN; NAUSEA; NOSE OBSTRUCTION; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; SORE THROAT; STOMACH DISCOMFORT; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; TREATMENT OUTCOME; UNITED STATES;

EID: 84874286376     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12042     Document Type: Article

References (36)

1. Birmaher B, Axelson D. Course and outcome of bipolar spectrum disorder in children and adolescents: a review of the existing literature. Dev Psychopathol 2006; 18: 1023-1035.
2. Delbello MP, Findling RL, Earley WR et al.Efficacy of quetiapine in children and adolescents with bipolar mania: a 3-week, double-blind, randomized, placebo-controlled trial. Poster presented at the 46th Annual Meeting of the American College of Neuropsychopharmacology, December 9-13 2007, Boca Raton, FL, USA.
3. Haas M, Delbello MP, Pandina G et al.Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2009; 11: 687-700.
4. Tohen M, Kryzhanovskaya L, Carlson G et al.Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164: 1547-1556.
5. Findling RL, Nyilas M, Fornes RA et al.Acute treatment of pediatric bipolar I disorder with aripiprazole: a randomized, bouble-blind, placebo-controlled study. J Clin Psychiatry 2009; 70: 1441-1451.
6. Findling RL, Youngstrom EA, McNamara NK et al.Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder. J Clin Psychiatry 2012; 73: 57-63.
7. Shapiro DA, Renock S, Arrington E et al.Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol 2003; 28: 1400-1411.
8. Stark AD, Jordan S, Allers KA et al.Interaction of the novel antipsychotic aripiprazole with 5-HT(1A) and 5-HT (2A) receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology 2007; 190: 373-382.
9. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004; 483: 45-53.
10. Keck PE Jr, Calabrese JR, McIntyre RS et al.Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 1480-1491.
11. Keck PE Jr, Calabrese JR, McQuade RD et al.A randomized, double-blind, placebo-controlled 26-Week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626-637.
12. Keck PE Jr, Marcus R, Tourkodimitris S et al.A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651-1658.
13. Sachs G, Sanchez R, Marcus R et al.Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20: 536-546.
14. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
15. Kaufman J, Birmaher B, Brent D et al.Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36: 980-988.
16. Shaffer D, Gould MS, Brasic J et al.A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983; 40: 1228-1231.
17. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159-171.
18. Findling RL, Youngstrom EA, Danielson CK et al.Clinical decision-making using the General Behavior Inventory in juvenile bipolarity. Bipolar Disord 2002; 4: 34-42.
19. Youngstrom EA, Findling RL, Danielson CK, Calabrese JR. Discriminative validity of parent report of hypomanic and depressive symptoms on the General Behavior Inventory. Psychol Assess 2001; 13: 267-276.
20. Reid R, DuPaul GJ, Power TJ et al.Assessing culturally different students for attention deficit hyperactivity disorder using behavior rating scales. J Abnorm Child Psycho 1998; 26: 187-198.
21. Endicott J, Nee J, Yang R, Wohlberg C. Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q): reliability and validity. J Am Acad Child Adolesc Psychiatry 2006; 45: 401-407.
22. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19.
23. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676.
24. Guy W. Abnormal Involuntary Movement Scale (AIMS). US Department of Health Education and Welfare ECDEU Assessment Manual for Psychopharmacology. Rockville: National Institutes of Mental Health, 1976: 534-537.
25. McConville B, Carrero L, Sweitzer D et al.Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol 2003; 13: 75-82.
26. Pavuluri MN, Henry DB, Carbray JA, Sampson G, Naylor MW, Janicak PG. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord 2004; 82 (Suppl. 1): S103-S111.
27. Findling R, Delbello M, Wang P et al.Long-term safety and tolerability of ziprasidone in children and adolescents with bipolar disorder. Poster presented at the 55th Annual Meeting of American Academy of Child and Adolescent Psychiatry October 28 to November 2, 2007, Chicago, IL, USA.
28. Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry 2005; 62: 1305-1312.
29. Biederman J, Mick E, Hammerness P et al.Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 2005; 58: 589-594.
30. DelBello MP, Kowatch RA, Adler CM et al.A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45: 305-313.
31. Frazier JA, Biederman J, Tohen M et al.A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001; 11: 239-250.
32. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008; 69 (Suppl. 4): 26-36.
33. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl. 1): 1-93.
34. ADA/APA/AACE/NAASO. Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Diabetes Care 2004; 27: 596-601.
35. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-1773.
36. Montgomery SA. Alternatives to placebo-controlled trials in psychiatry. ECNP Consensus Meeting, September 26, 1996, Amsterdam. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 1999; 9: 265-269.